What’s Driving Johnson & Johnson Stock

What's Driving Johnson & Johnson Stock?

Question: What drove JNJ stock up 70% since early 2025?

The short answer: investor sentiment did most of the work, with actual business performance playing a supporting role.

JNJ went from ~$140 early last year to $237 today - a 70% gain. When you decompose it, 60 percentage points came from P/S multiple expansion (from 3.8x to 6.1x), and only about 6 points came from revenue growth. In other words, for every dollar of value created, roughly 90 cents was the market paying more for the same earnings stream, not the earnings stream itself growing. That's a significant distinction.

Part 1: The Revenue Story - Real But Modest

Did the business actually grow? Yes. Johnson & Johnson's revenue rose from $88.8B in 2024 to $94.2B in 2025 - a 6% increase. Shares outstanding were essentially flat, so revenue per share grew by the same amount.

What drove the revenue growth? Both the engines: Innovative Medicine and MedTech.

On the pharma side, growth was driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT in Oncology, TREMFYA and SIMPONI in Immunology, and SPRAVATO in Neuroscience - though this was partially offset by roughly 1,040 basis points of headwind from STELARA biosimilar competition. That's notable: STELARA's patent expiry was a meaningful drag, and the rest of the portfolio had to run hard just to offset it.

On the devices side, MedTech grew 5.4% operationally, driven by electrophysiology products and Abiomed in Cardiovascular, and wound closure products in General Surgery.

So the revenue growth was real and broad-based - but at 6%, it's not the kind of explosive top-line expansion that typically justifies a 60% multiple re-rating on its own.

Part 2: The Multiple Expansion - Where the Real Story Is

If revenue only grew 6%, why did investors pay 60% more for each dollar of revenue?

Three structural shifts changed how the market thinks about JNJ as a business:

1. The Kenvue Spinoff - Shedding the Slow Lane: The 2023 spin-off of the consumer health business (Tylenol, Band-Aid, Neutrogena) was transformative. By shedding the lower-margin, slower-growing Kenvue division, J&J essentially traded "Tylenol stability" for "Oncology velocity." What remained was a pure-play Innovative Medicine and MedTech company - a fundamentally different, higher-growth, higher-margin profile than the old conglomerate. The market was slow to price this in during 2023-2024, but the re-rating largely played out through 2025, with the P/E reaching levels well above the 5-year historical average as the market finally priced in the "Kenvue-less" growth profile. Furthermore, investors are also cheering for the orthopedics spin-off expected this year.
2. Pipeline Credibility - A Portfolio Worth Paying For: J&J's management described 2025 as a "catapult year," driven by the strongest portfolio and pipeline in the company's history - and the market appeared to agree. J&J had 28 "priority platforms" - products each capable of generating over $1 billion in annual revenue - including cell therapy CARVYKTI, which joined the billion-dollar club in late 2025. Investors were not just paying for current revenue; they were paying for a visible, crowded pipeline in high-value therapeutic areas like oncology, cardiovascular, and neuroscience. The $14.6 billion acquisition of Intra-Cellular Therapies - adding CAPLYTA and a robust CNS portfolio - meaningfully expanded the neuropsychiatry business, signaling that management was willing to deploy capital aggressively to sustain growth beyond the STELARA cliff.
3. Margin Expansion Expectations: JNJ maintained guidance for approximately 300 basis points of operating margin improvement for the full year, driven by efficiency programs. Investors buying a company with accelerating margins on a P/S basis are essentially betting that the profitability per revenue dollar will be higher tomorrow than today - which justifies paying more for that revenue today. With the low-margin consumer business gone and MedTech margins expanding, this was a credible narrative.

The Overhang That Kept the Multiple From Going Higher

So why didn't the stock go even further? The talc litigation remains a persistent discount on the multiple.

Over 67,000 plaintiffs are still suing J&J over talc-related cancer claims. Following the rejection of its third bankruptcy attempt in March 2025, J&J returned to the tort system - keeping a cloud of uncertainty over the stock. JNJ's forward P/E sits at a discount to historical averages specifically because of this litigation overhang.

What does resolution mean for the stock? Potentially a lot. Analysts widely view removing this legal cloud as the primary catalyst for a significant further re-rating. In other words, the 60% multiple expansion that's already happened may not be the end of the story - it's arguably the story with a known discount still baked in.

Bottom Line

JNJ's 70% run since the end of 2024 is predominantly a valuation story, not an earnings story. We saw this coming and talked about it in Q3 last year - Is Rerating Around The Corner For Johnson & Johnson Stock? See, the business grew - oncology and MedTech delivered, acquisitions added credibility to the pipeline, and margins are improving. But the real driver was a structural re-rating as the market recalibrated what J&J is now: a focused, high-margin, innovation-led healthcare company, not the sprawling consumer-pharma conglomerate it was. The revenue growth validated the thesis; the multiple expansion was the thesis.

Still unsure of JNJ stock? Consider the portfolio approach.

The Right Way To Invest Is Through Portfolios

Individual stocks are unpredictable. A smart portfolio helps you invest, limits downside shocks, and provides upside exposure.

Why settle for average market returns? The Trefis High Quality (HQ) Portfolio invests in a diverse group of 30 stocks that have collectively delivered stronger upside with reduced volatility compared to the broader indices. Discover the methodology behind these smoother, higher returns by checking the HQ Portfolio performance data.

Invest with Trefis Market-Beating Portfolios

See all Trefis Price Estimates